2-(4,5-二氯-2-硝基苯基)乙酸 | 37777-90-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(4,5-二氯-2-硝基苯基)乙酸
• 中文别名: 二氯硝基苯乙酸
• 英文名称: 2-nitro-4,5-dichlorophenylacetic acid
• 英文别名: 4,5-dichloro-2-nitrophenylacetic acid；4,5-Dichloro-2-nitro-phenylacetic acid；4,5-Dichlor-2-nitro-phenylessigsaeure；2-(4,5-Dichloro-2-nitrophenyl)acetic acid
• CAS: 37777-90-5
• 化学式: C₈H₅Cl₂NO₄
• 分子量: 250.038
• InChiKey: NIBVBDGBJQMRNF-UHFFFAOYSA-N

物化性质

• 熔点：
  127-130°
• 沸点：
  388.0±37.0 °C(Predicted)
• 密度：
  1.638±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2916399090

反应信息

• 作为反应物：
  描述：

  2-(4,5-二氯-2-硝基苯基)乙酸 在 platinum(IV) oxide 咪唑 、 硫酸 、 氢气 、 sodium methylate 、 sodium hydride 、 溶剂黄146 、 三氯氧磷 作用下， 以 甲醇 、 1,2-二氯乙烷 、 乙腈 为溶剂， 20.0 ℃ 、275.8 kPa 条件下， 反应 32.0h， 生成 1-(2-deoxy-β-D-erythro-pentofuranosyl)-2,5,6-trichloroindole
  参考文献：
  名称：

  Synthesis and Antiviral Evaluation of Trisubstituted Indole N-Nucleosides as Analogues of 2,5,6-Trichloro-1-(β-d-ribofuranosyl)benzimidazole (TCRB)

  摘要：

  2,5,6-Trichloro-1-(beta-D-ribofuranosyl)benzimidazole (TCRB) and 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole (BDCRB) are nucleosides that exhibit strong and selective activity against human cytomegalovirus (HCMV). Selected polyhalogenated indole nucleosides have now been synthesized as 3-deaza analogues of the benzimidazole nucleosides using the sodium salt glycosylation method. 2-Benzylthio-1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-beta-D-erythropentofuranosyl]-5,6-dichloroindole (8) was prepared stereoselectively via the coupling of a 2-deoxyribofuranosyl alpha-chloride derivative with the sodium salt of 2-benzylthio-5,6-dichloroindole (5). Compound 8 was then elaborated into the targeted 2-benzylthio-1-(beta-D-ribofuranosyl)-5,6-dichloroindole (18) in five steps. 2,5,6-Trichloro-(1-beta-D-ribofuranosyl)indole (19) was prepared using the same synthetic route with 2,5,6-trichloroindole (6) as the starting material. We were subsequently able to prepare 19 in three steps using a modification of the sodium salt glycosylation method. 2-Bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)indole (25) was also prepared using the same procedures. Target compounds were tested for activity against HCMV, herpes simplex virus type 1 (HSV-1), and human herpes virus six (HHV-6) and for cytotoxicity. All of the compounds were less active against HCMV than TCRB and weakly active or inactive against HSV-1 and HHV-6.

  DOI：

  10.1021/jm990320x
• 作为产物：
  描述：

  3,4-二氯苯乙酸 在 硫酸 、 硝酸 作用下， 以70%的产率得到2-(4,5-二氯-2-硝基苯基)乙酸
  参考文献：
  名称：

  合成破骨细胞抑制剂SB-242784

  摘要：

  破骨细胞抑制剂SB-242784（1）是由关键的吲哚中间体4制备的。有机锡2c与溴化丙烯酸酯11的“ Stille”交叉偶联提供了二烯12，它也是通过烯炔16的还原异构化过程获得的。溴酰胺3是由相应的酸制备7将其容易地从溴丙酮酸获得。

  DOI：

  10.1016/s0040-4039(03)00544-6

文献信息

• Kappa agonist compounds and pharmaceutical formulations thereof
  申请人：——

  公开号：US20030144272A1

  公开（公告）日：2003-07-31

  Compounds having kappa opioid agonist activity, compositions containing them and method of using them as analgesics are provided. The compounds of formulae I, II, IIA, III, IIIA, IIIB, IIIB-i, IV and IVA have the structure: 1 2 wherein R 1 , R 2 , R 3 , R 4 ; and X, X 4 , X 5 , X 7 , X 9 ; Y, Z and n are as described in the specification.

  提供具有kappa阿片受体激动剂活性的化合物，含有这些化合物的组合物以及使用它们作为镇痛剂的方法。 具有以下结构的化合物I、II、IIA、III、IIIA、IIIB、IIIB-i、IV和IVA： 1 2 其中 R 1 ，R 2 ，R 3 ，R 4 ；和 X，X 4 ，X 5 ，X 7 ，X 9 ； Y，Z和n如规范中所述。
• Kappa agonist compounds pharmaceutical formulations and method of
  申请人：Adolor Corporation

  公开号：US06057323A1

  公开（公告）日：2000-05-02

  Compounds having kappa opioid agonist activity, compositions containing them and method of using them as analgesics and anti-pruritic agents are provided. The compound of formula I, having the structure: ##STR1## wherein R.sub.1, R.sub.2 ; X; and Ar Y, Z and n are as described in the specification.

  提供具有kappa阿片受体激动剂活性的化合物、含有这些化合物的组合物以及将它们用作镇痛剂和抗瘙痒剂的方法。具有结构的I式化合物：##STR1##其中R.sub.1，R.sub.2；X；和Ar Y，Z和n如规范中描述。
• Aminotetralin derivatives
  申请人：Dr. Karl Thomae GmbH

  公开号：US04584293A1

  公开（公告）日：1986-04-22

  This invention related to new aminotetralin derivatives of formula I ##STR1## wherein ##STR2## B is methylene or, when A is --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH--, --NH--CO-- or --CH.sub.2 --CO--, B can also be carbonyl or thiocarbonyl; E is a C.sub.2 -C.sub.4 straight-chain alkylene, optionally substituted by a C.sub.1 -C.sub.3 alkyl, or is 2-hydroxy-n-propylene, 2-hydroxy-n-butylene or 3-hydroxy-n-butylene; R.sub.1 is hydrogen, fluorine, chlorine, bromine, trifluoromethyl, nitro, amino, C.sub.1 -C.sub.3 alkylamino, C.sub.1 -C.sub.3 dialkylamino, C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkylthio, hydroxy, C.sub.1 -C.sub.3 alkoxy or phenyl C.sub.1 -C.sub.3 alkoxy; R.sub.2 is hydrogen, chlorine, bromine, hydroxy, C.sub.1 -C.sub.3 alkoxy phenyl C.sub.1 -C.sub.3 alkoxy, or C.sub.1 -C.sub.3 alkyl or, together with R.sub.1, can be a C.sub.1 -C.sub.2 alkylenedioxy; R.sub.3 and R.sub.4 are each independently selected from hydrogen, fluorine, chlorine, bromine, C.sub.1 -C.sub.3 alkyl, hydroxy, C.sub.1 -C.sub.3 alkoxy, nitro, amino, C.sub.1 -C.sub.3 alkylamino, or C.sub.1 -C.sub.3 dialkylamino, or together can be methylenedioxy; and R.sub.5 is hydrogen, C.sub.3 -C.sub.5 alkenyl, C.sub.1 -C.sub.3 alkyl, or phenyl C.sub.1 -C.sub.3 alkyl, and nontoxic, pharmaceutically acceptable addition salts thereof which have valuable pharmacological properties, particularly a long-lasting heart rate lowering effect and the effect of reducing the O.sub.2 requirement of the heart.

  这项发明涉及公式I的新的氨基四氢萘衍生物，其中B是亚甲基，当A是--CH.sub.2--CH.sub.2--时，B也可以是羰基或硫代羰基；E是一种C.sub.2-C.sub.4直链烷基，可以选择性地被C.sub.1-C.sub.3烷基取代，或者是2-羟基-n-丙烷基，2-羟基-n-丁烷基或3-羟基-n-丁烷基；R.sub.1是氢、氟、氯、溴、三氟甲基、硝基、氨基、C.sub.1-C.sub.3烷基氨基、C.sub.1-C.sub.3二烷基氨基、C.sub.1-C.sub.3烷基、C.sub.1-C.sub.3烷基硫、羟基、C.sub.1-C.sub.3烷氧基或苯基C.sub.1-C.sub.3烷氧基；R.sub.2是氢、氯、溴、羟基、C.sub.1-C.sub.3烷氧基苯基C.sub.1-C.sub.3烷氧基、或C.sub.1-C.sub.3烷基或者与R.sub.1一起可以是C.sub.1-C.sub.2烷二氧基；R.sub.3和R.sub.4各自独立地选自氢、氟、氯、溴、C.sub.1-C.sub.3烷基、羟基、C.sub.1-C.sub.3烷氧基、硝基、氨基、C.sub.1-C.sub.3烷基氨基或C.sub.1-C.sub.3二烷基氨基，或者一起可以是亚甲基二氧基；R.sub.5是氢、C.sub.3-C.sub.5烯丙基、C.sub.1-C.sub.3烷基或苯基C.sub.1-C.sub.3烷基，以及其无毒的、药学上可接受的盐，具有有价值的药理学特性，特别是长效降低心率和减少心脏对O.sub.2需求的作用。
• Antimalarial phenanthrene amino alcohols. 3. Halogen-containing 9-phenanthrenemethanols
  作者：Edward A. Nodiff、Andrew J. Saggiomo、Keiichi Tanabe、Eugene H. Chen、Masafu Shinbo、Mahesh P. Tyagi、Atsuto Kozuka、Hirotaka Otomasu、Basant L. Verma、David Goff

  DOI：10.1021/jm00244a012

  日期：1975.10

  A series of new 9-phenanthrene amino alcohols has been prepared in which each compound bears from one to five halogen or halogen-containing moieties. A number of these compounds are extremely active against Plasmodium berghei in the mouse. Some structural requirements for optimal efficacy are considered.

  已经制备了一系列新的9-菲氨基醇，其中每种化合物带有一个至五个卤素或含卤素的部分。这些化合物中的许多对小鼠中的伯氏疟原虫具有极强的活性。考虑了最佳功效的一些结构要求。
• Towards the synthesis of osteoclast inhibitor SB-242784
  作者：Jose J. Conde、Michael McGuire、Michael Wallace

  DOI：10.1016/s0040-4039(03)00544-6

  日期：2003.4

  Osteoclast inhibitor SB-242784 (1) was prepared from pivotal indol intermediate 4. A ‘Stille’ cross coupling of organotin 2c with bromo acrylate 11 afforded diene 12 which was also obtained via a reduction–isomerization process of enyne 16. Bromoamide 3 was prepared from the corresponding acid 7 which was readily obtained from bromopyruvic acid.

  破骨细胞抑制剂SB-242784（1）是由关键的吲哚中间体4制备的。有机锡2c与溴化丙烯酸酯11的“ Stille”交叉偶联提供了二烯12，它也是通过烯炔16的还原异构化过程获得的。溴酰胺3是由相应的酸制备7将其容易地从溴丙酮酸获得。